Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer
© BioMed Central Ltd 2009
Published: 12 May 2009
Using fluorescence in situ hybridization (FISH), we previously showed that the LRIG1 gene had an increased copy number in 11 of 28 (39%) breast cancer tumours . The LRIG1 gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product ERBB2 [2, 3].
We draw the following major conclusions from these results. First, as previously shown, a significant proportion of breast tumours have an increased LRIG1 gene dosage. Second, there is a correlation between increased gene copy numbers of ERBB2 and LRIG1. Third, based on the Miller protein data, most of the tumours with increased LRIG1 gene dosage express reduced levels of the LRIG1 protein. This indicates a negative selection against LRIG1 protein expression, supporting the notion that LRIG1 is a tumour suppressor in breast cancer. Although the mechanism behind the down-regulation of LRIG1 protein in breast cancer is not known, it has been reported that increased gene copy numbers in some cases are associated with decreased mRNA expression . In any case, the high frequency (34%) of tumours with increased LRIG1 gene copy number implies a positive selection for tumour cells with this genomic alteration. It remains, however, to be elucidated whether the molecular driver behind the selective advantage associated with this alteration is LRIG1 down-regulation per se. Other possibilities include activation of nearby proto-oncogenes or the generation of novel oncogenic fusion genes.
In summary, the co-incidental increase in copy number of ERBB2 and LRIG1 in breast cancer is a novel finding, pointing at a functional co-operation between these genetic events, where the biological and clinical importance need to be clarified further.
fluorescence in situ hybridization.
- Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, Emdin S, Jonsson Y, Hedman H, Henriksson R: Increased copy number at 3p14 in breast cancer. Breast Cancer Res. 2005, 7: R719-727. 10.1186/bcr1279.PubMedPubMed CentralView ArticleGoogle Scholar
- Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004, 23: 3270-3281. 10.1038/sj.emboj.7600342.PubMedPubMed CentralView ArticleGoogle Scholar
- Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, Sweeney C: The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 2004, 279: 47050-47056. 10.1074/jbc.M409703200.PubMedView ArticleGoogle Scholar
- Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL, Sweeney C: Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res. 2008, 68: 8286-8294. 10.1158/0008-5472.CAN-07-6316.PubMedPubMed CentralView ArticleGoogle Scholar
- Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavaré S, Deloukas P, Hurles ME, Dermitzakis ET: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science. 2007, 315: 848-853. 10.1126/science.1136678.PubMedPubMed CentralView ArticleGoogle Scholar